Multiple Sclerosis Clinical Trial
Official title:
Effect of Need to Void on Gait Speed in Multiple Sclerosis
Verified date | July 2019 |
Source | Pierre and Marie Curie University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Multiple sclerosis causes demyelinating lesions, which can induce multiple symptoms. If motor
disorders are the most visible disability, urinary disorders are frequent, with prevalence
from 32 to 86%. The first ones are due to pyramidal, cerebellar or proprioceptive lesions.
The seconds are due to specific lesion in inhibitor/activator encephalic centers, or
interruption on medullary conduction. It seems to be evident that walk and urinary disorders
are link, because of similar anatomic ways and control process. Effect of bladder filling is
well known on motoneuronal excitability. The effect of bladder filling on walk stay unknown,
while medullary integration of these two functions is very close, in medullary cone.
Primary aim is to assess the effect of need to void on walk speed in multiple sclerosis with
lower urinary tract symptoms. Secondary aim is to identify clinical or urodynamic factor link
with major walk impairment when patients need to void.
Patient with multiple sclerosis over 18 years old, consulting for lower urinary tract
symptoms in a tertiary center are included.
History and treatment, high, weigh, symptoms severity by USP score, cognitive impairment by
MMSE score and last urodynamic data are recorded. Patient are asked to drink water until they
feel a strong need to void, for which they would go to urinate at home.
Walk tests are realized in a specific place, with calm and no passage. A chair is placed at
each end of the path. Toilets are just next to the hall where they realize the tests. A 10
Meters Walk Test is done during this condition, 3 times (only the intermediate 6 meters are
recorded). They can take 30 seconds of rest between each try if necessary. One Timed up and
go is done. Patient can use their habitual walking device. Speed walk asking is comfortable
for the two test.
Next, patient can urinate. 3 post void residual volume with portable echography are done, and
the higher is recorded.
Patient achieve the same walk tests after urinate, in the same order. They must use the same
walking device.
Primary outcome is mean gait recorded for 10 meters walk test.
Secondary outcome is time for timed up and go test.
Individual variability between the 3 10MWT in the two conditions will be study.
Influence of age, EDSS, severity of symptoms, MMSE, detrusor overactivity on speed impairment
will be study in secondary analysis.
Status | Completed |
Enrollment | 71 |
Est. completion date | August 31, 2017 |
Est. primary completion date | August 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Multiple sclerosis - Follow in neuro-urology for lower urinary tract symtpoms - Able to walk 50 meters without human assistance - able to hold on void during 3 minutes at least Exclusion Criteria: - actual urinary tract infection - relapse in the last week - Mini Mental State Examination < 10 |
Country | Name | City | State |
---|---|---|---|
France | Service de Neuro-urology, hôpital Tenon | Paris |
Lead Sponsor | Collaborator |
---|---|
Pierre and Marie Curie University |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gait speed | Gait speed calculated from 10 meter walk test. Only the 6 intermediate meters are recorded. Time is recorded by a manual chronometer. 3 records are done, mean time is calculated. Mean time is divided by 6 to obtain mean gait speed | 1 Day: at strong desire to void and just after void | |
Secondary | Time for Timed up and Go | 1 record is done for timed up and go test after a first training. Time is recorded by a manual chronometer | 1 Day: at strong desire to void and just after void | |
Secondary | Variation of gait speed | Coefficient of variation is calculated from the 3 records of 10 meter walk test. It correspond to standard deviation/average. | 1 Day: for strong desire to void and post void |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |